AGP Picks
View all

Lumea’s BxBoard® Named Top 3 Finalist in Utah Innovation Awards MedTech Category

Lumea Wins a Utah Business Innovation Award 2026

Revolutionary sponge-fixation transport system recognized for modernizing prostate cancer diagnostics and preserving tissue integrity.

LEHI, UT, UNITED STATES, September 8, 2026 /EINPresswire.com/ -- Lumea today announced its BxBoard® biopsy transportation and preservation container has been ranked third in the MedTech Devices & Diagnostics category for the 2026 Utah Innovation Awards. Presented by Utah Business and Nucleus, the awards recognize the state’s most pioneering technological advancements driving meaningful change across Utah’s healthcare landscape.

“We are thrilled to be ranked among the top three innovators in this category and honored to stand alongside so many visionary Utah companies,” said James Thackeray, Lumea CEO. “This recognition validates our commitment to solving a decades-old problem in pathology and ensuring clinicians have the best possible information to determine treatment pathways for their patients.”

The BxBoard replaces the standard formaldehyde jars historically used for prostate biopsies, which frequently led to tissue breakage, curling, and compromised specimen integrity. Lumea's purpose-built container allows up to six delicate prostate biopsies to be placed flat on a formalin-soaked sponge within individual lanes. This design preserves tissue orientation from the moment of collection, fundamentally transforming downstream workflows for lab technicians.

Currently deployed across more than 130 U.S. clinics, clinical studies show the BxBoard dramatically improves specimen quality compared to traditional jar methods. Key clinical impacts include:
- A 35% reduction in core fragmentation and a 28% increase in measurable core length.
- A 2.1x reduction in test cancellations due to insufficient quantity or RNA degradation.
- A 92.5% reduction in formaldehyde use per case, significantly reducing lab tech exposure to carcinogens.
- An 83% reduction in collection containers, blocks, and slides required for diagnosis.

About the Utah Business Innovation Awards
The Utah Business Innovation Awards are presented annually by Utah Business to honor the state's most pioneering startups, visionary entrepreneurs, and breakthrough technological advancements. Nominees undergo an evaluation by business, civic, and academic leaders based on product novelty, market need, economic impact, and disruption of the status quo. To learn more, visit utahbusiness.com.

About Lumea
Lumea is powering efficient, affordable, and accessible digital pathology through simplified, workflow-driven innovation with both tissue-handling technology and a best-in-class viewer with AI-driven workflows. As the U.S. leader in primary clinical digital pathology, processing the highest volume of digital cases nationwide, Lumea has set the standard for efficiency, quality, and premium cancer diagnostics. With a global presence spanning five continents, Lumea supports over half of the U.S. urology market and top dermatology and gastroenterology groups, optimizing tissue integrity, boosting detection rates, and delivering measurable ROI. By placing patients at the core, Lumea is transforming pathology for a more precise and efficient future. Learn more at lumeadigital.com.

Bianca Collings
Lumea
email us here
Visit us on social media:
LinkedIn
Instagram
YouTube
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Today in Science

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.